Characteristics and prognosis of primary treatment-naïve oral cavity squamous cell carcinoma in Norway, a descriptive retrospective study

PLoS One. 2020 Jan 16;15(1):e0227738. doi: 10.1371/journal.pone.0227738. eCollection 2020.

Abstract

Objectives: Incidence of oral cavity squamous cell carcinomas is rising worldwide, and population characterization is important to follow for future trends. The aim of this retrospective study was to present a large cohort of primary oral cavity squamous cell carcinoma from all four health regions of Norway, with descriptive clinicopathological characteristics and five-year survival outcomes.

Materials and methods: Patients diagnosed with primary treatment-naïve oral cavity squamous cell carcinomas at all four university hospitals in Norway between 2005-2009 were retrospectively included in this study. Clinicopathological data from the electronic health records were compared to survival data.

Results: A total of 535 patients with primary treatment-naïve oral cavity squamous cell carcinomas were identified. The median survival follow-up time was 48 months (range 0-125 months) after treatment. The median five-year overall survival was found to be 47%. Median five-year disease-specific survival was 52%, ranging from 80% for stage I to 33% for stage IV patients. For patients given treatment with curative intent, the overall survival was found to be 56% and disease-specific survival 62%. Median age at diagnosis was 67 years (range 24-101 years), 64 years for men and 72 years for women. The male: female ratio was 1.2. No gender difference was found in neither tumor status (p = 0.180) nor node status (p = 0.266), but both factors influenced significantly on survival (p<0.001 for both).

Conclusions: We present a large cohort of primary treatment-naïve oral cavity squamous cell carcinomas in Norway. Five-year disease-specific survival was 52%, and patients eligible for curative treatment had a five-year disease-specific survival up to 62%.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Chemoradiotherapy, Adjuvant / methods
  • Female
  • Follow-Up Studies
  • Humans
  • Lymphatic Metastasis / pathology*
  • Lymphatic Metastasis / therapy
  • Male
  • Middle Aged
  • Mouth Mucosa / pathology
  • Mouth Mucosa / surgery
  • Mouth Neoplasms / mortality*
  • Mouth Neoplasms / pathology
  • Mouth Neoplasms / therapy
  • Neck Dissection
  • Neoadjuvant Therapy / methods
  • Neoplasm Staging
  • Norway / epidemiology
  • Prognosis
  • Retrospective Studies
  • Squamous Cell Carcinoma of Head and Neck / mortality*
  • Squamous Cell Carcinoma of Head and Neck / pathology
  • Squamous Cell Carcinoma of Head and Neck / therapy
  • Survival Analysis
  • Time Factors
  • Treatment Outcome
  • Young Adult

Grants and funding

The work was supported by grants from the North Norwegian Regional Health Authorities. The publication charges for this article have been funded by a grant from the publication fund of UiT The Arctic University of Norway. The funders had no role in study design, data collection, decision to publish, or preparation of the manuscript.